|
|
|
|
|
|
 | Cancer in older patients: an analysis of elderly oncology
| | V Swaminathan and RA Audisio |  | Tumor-infiltrating granulocytic cells promote cancer cell dissemination
| | B Toh and JP Abastado |  | Pregnant with metastatic neuroendocrine tumour of the ovary: what now?
| | B Pistilli, CM Grana, N Fazio, A Cavaliere, ME Ferrari, L Bodei, SM Baio, G Scambia, G Paganelli and FA Peccatori |  | A dedicated website for cancer subjects, the nutritional support study: preliminary results
| | P Gnagnarella, AM Misotti, L Santoro, D Akoumianakis, G Milolidakis, F De Lorenzo, C Lombardo, R Sullivan and G Mcvie |  | To know or not to know? Not the only question in familial breast cancer risk communication
| | C Maddock, D Schrijvers, MRD Turco, L Marotti and R Sullivan |  | Endocrine-responsive breast cancer: a 28-year Odyssey
| | A West, KP Friedman and F Muggia |  | Better, and 'healthier' decision making through information technology: Conference Report from the Health 2.0 Conference in San Francisco, Sept 2011
| | S Camporesi |  | Muscle metastases from gallbladder cancer
| | L Gilardi, G Paganelli |
|
|  | | |
|
|
 | Evolving treatment options in castration-resistant prostate cancer
Prof Gordon Mcvie, Prof Johann De Bono, Prof Bertrand Tombal, Prof Juergen Gschwend, Dr Maria De Santis |  | The latest in prostate cancer imaging
Prof Anwar Padhani - Mount Vernon Cancer Institute, UK |  | What drives improvements in cancer care?
Prof Kurt Miller, Prof Gordon McVie, Dr Karim Fizazi, Peter Hazenberg, Jane Griffiths |  | Discussion on treating advanced prostate cancer
Dr Bertrand Tombal – Saint-Luc Hospital, Brussels, Belgium; Dr Dominik Berthold – Multidisciplinary Oncology Center, Lausanne, Switzerland; Dr Amit Bahl – Bristol Haematology and Oncology Centre, UK; Dr Florian Scotte – Hopital Europeen Georges Pompidou, Paris, France |  | Best practices in patient management in mCRPC
Dr Florian Scotte – Hopital Europeen Georges Pompidou, Paris, France |  | New options for patients progressing after first line chemotherapy
Dr Amit Bahl – Bristol Haematology and Oncology Centre, UK |  | The importance of risk stratification to guide treatment of mCRPC
Dr Dominik Berthold – Multidisciplinary Oncology Center, Lausanne, Switzerland |  | The changing paradigm in mCRPC treatment
Dr Bertrand Tombal – Saint-Luc Hospital, Brussels, Belgium |  | BTK inhibitor PCI-32765 induces durable responses in relapsed or refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma
Prof Susan O’Brien - University of Texas MD Anderson Cancer Center, Houston |  | Obinutuzumab with rituximab in patients with relapsed CD20 and indolent B-Cell non-hodgkin lymphoma (GAUSS)
Dr Laurie Sehn - University of British Columbia, Vancouver, Canada |
|
|
| | | |
|
| |
